13:08 uur 27-10-2020

Crown Bioscience vergroot APAC-capaciteit met nieuwe faciliteit in Zhongshan, China

SAN DIEGO, Californië – (BUSINESS WIRE) – Crown Bioscience, een JSR Life Sciences-bedrijf, kondigt vandaag de opening aan van een nieuwe op oncologie gerichte onderzoeksfaciliteit in Zhongshan, China om aan de toegenomen vraag van klanten te voldoen.

Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/20201027005098/en/

Naast de vier vestigingen van het bedrijf in de VS en Europa, omvat CrownBio’s bestaande APAC-voetafdruk momenteel drie vestigingen in Beijing, Taicang en Suzhou, evenals één in Taiwan. Na voltooiing zal dit nieuwe gebouw meer dan 2.000 m2 nieuwe vivariumruimte toevoegen ter ondersteuning van CrownBio’s in vivo oncologieplatforms, waardoor de voorspelde groei op korte termijn kan worden voldaan.

Crown Bioscience Increases APAC Capacity with New Facility in Zhongshan, China

SAN DIEGO, Calif.–(BUSINESS WIRE)– Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/

CrownBio's New Zhongshan, China Facility (Photo: Business Wire)

CrownBio’s New Zhongshan, China Facility (Photo: Business Wire)

In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.

CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.

The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.

“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.

A site opening event and ribbon cutting ceremony will take place on October 30th 2020.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:




Media Enquiries:
Jody Barbeau

Crown Bioscience Inc.


Check out our twitter: @NewsNovumpr